Stock Track | Hims & Hers Health Soars 5.05% as Weight-Loss Drug Partnership Boosts Investor Confidence

Stock Track

May 01, 2025

Hims & Hers Health Inc. (HIMS) saw its stock soar by 5.05% during Thursday's intraday trading, as investors reacted positively to the company's recent partnership in the booming weight-loss medication market. The surge comes amid growing interest in GLP-1 drugs and their potential in the telehealth sector.

The rally in Hims & Hers stock appears to be driven by its recently announced partnership with Novo Nordisk, a leading pharmaceutical company known for its blockbuster weight-loss drug, Wegovy. This collaboration positions Hims & Hers as a key player in the distribution of these increasingly popular medications through its telehealth platform, potentially opening up new revenue streams and growth opportunities for the company.

The weight-loss medication market has been gaining significant attention from both healthcare providers and investors. CVS Health, another major player in the healthcare space, also announced plans to make Wegovy a preferred drug on its formulary and partner with Novo Nordisk's NovoCare platform. These industry-wide developments underscore the growing importance of weight-loss medications in the healthcare landscape and highlight the potential for companies like Hims & Hers to benefit from this trend.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1138455577"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1138455577\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1138455577?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-01 22:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138455577","market":"us","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 5.05% as Weight-Loss Drug Partnership Boosts Investor Confidence","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) saw its stock soar by 5.05% during Thursday's intraday trading, as investors reacted positively to the company's recent partnership in the booming weight-loss medication market. The surge comes amid growing interest in GLP-1 drugs and their potential in the telehealth sector.</p>\n\n<p>The rally in Hims & Hers stock appears to be driven by its recently announced partnership with Novo Nordisk, a leading pharmaceutical company known for its blockbuster weight-loss drug, Wegovy. This collaboration positions Hims & Hers as a key player in the distribution of these increasingly popular medications through its telehealth platform, potentially opening up new revenue streams and growth opportunities for the company.</p>\n\n<p>The weight-loss medication market has been gaining significant attention from both healthcare providers and investors. CVS Health, another major player in the healthcare space, also announced plans to make Wegovy a preferred drug on its formulary and partner with Novo Nordisk's NovoCare platform. These industry-wide developments underscore the growing importance of weight-loss medications in the healthcare landscape and highlight the potential for companies like Hims & Hers to benefit from this trend.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 5.05% as Weight-Loss Drug Partnership Boosts Investor Confidence</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 5.05% as Weight-Loss Drug Partnership Boosts Investor Confidence\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-01 22:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hims & Hers Health Inc. (HIMS) saw its stock soar by 5.05% during Thursday's intraday trading, as investors reacted positively to the company's recent partnership in the booming weight-loss medication market. The surge comes amid growing interest in GLP-1 drugs and their potential in the telehealth sector.</p>\n\n<p>The rally in Hims & Hers stock appears to be driven by its recently announced partnership with Novo Nordisk, a leading pharmaceutical company known for its blockbuster weight-loss drug, Wegovy. This collaboration positions Hims & Hers as a key player in the distribution of these increasingly popular medications through its telehealth platform, potentially opening up new revenue streams and growth opportunities for the company.</p>\n\n<p>The weight-loss medication market has been gaining significant attention from both healthcare providers and investors. CVS Health, another major player in the healthcare space, also announced plans to make Wegovy a preferred drug on its formulary and partner with Novo Nordisk's NovoCare platform. These industry-wide developments underscore the growing importance of weight-loss medications in the healthcare landscape and highlight the potential for companies like Hims & Hers to benefit from this trend.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1138455577","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138455577","pubTimestamp":1746111402,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc.  saw its stock soar by 5.05% during Thursday's intraday trading, as investors reacted positively to the company's recent partnership in the booming weight-loss medication market. The surge comes amid growing interest in GLP-1 drugs and their potential in the telehealth sector.The rally in Hims & Hers stock appears to be driven by its recently announced partnership with Novo Nordisk, a leading pharmaceutical company known for its blockbuster weight-loss drug, Wegovy. This ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票跟踪Hims&Hers Health飙升5.05%，减肥药合作增强了投资者信心","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) saw its stock soar by 5.05% during Thursday's intraday trading, as investors reacted positively to the company's recent partnership in the booming weight-loss medication market. The surge comes amid growing interest in GLP-1 drugs and their potential in the telehealth sector.\nThe rally in Hims & Hers stock appears to be driven by its recently announced partnership with Novo Nordisk, a leading pharmaceutical company known for its blockbuster weight-loss drug, Wegovy. This collaboration positions Hims & Hers as a key player in the distribution of these increasingly popular medications through its telehealth platform, potentially opening up new revenue streams and growth opportunities for the company.\nThe weight-loss medication market has been gaining significant attention from both healthcare providers and investors. CVS Health, another major player in the healthcare space, also announced plans to make Wegovy a preferred drug on its formulary and partner with Novo Nordisk's NovoCare platform. These industry-wide developments underscore the growing importance of weight-loss medications in the healthcare landscape and highlight the potential for companies like Hims & Hers to benefit from this trend.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}